Magnesium pidolate: Difference between revisions

Magnesium pidolate
Clinical data
AHFS/Drugs.com	Consumer Drug Information
ATC code	A12CC08 (WHO) ;
Identifiers
	IUPAC name Magnesium 5-oxopyrrolidine-2-carboxylate;
PubChem CID	9838620;
ChemSpider	8014340 ;
CompTox Dashboard (EPA)	DTXSID30905130 ;
ECHA InfoCard	100.080.955
Chemical and physical data
Formula	C10H12MgN2O6
Molar mass	280.517 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Mg+2].[O-]C(=O)C1NC(=O)CC1.[O-]C(=O)C1NC(=O)CC1;
	InChI InChI=1S/2C5H7NO3.Mg/c27-4-2-1-3(6-4)5(8)9;/h23H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2 ; Key:JQAACYUZYRBHGG-UHFFFAOYSA-L ;
	(verify)

Content deleted Content added

Inline

Revision as of 17:20, 1 September 2015

Magnesium pidolate, the magnesium salt of pidolic acid (pyroglutamic acid), is a mineral supplement.

De Franceschi L, Bachir D, Galacteros F, et al. (2000). "Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease". Br. J. Haematol. 108 (2): 284–9. doi:10.1046/j.1365-2141.2000.01861.x. PMID 10691856.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

@@ Line 49: / Line 49: @@
 ==External links==
-* {{cite journal |author=De Franceschi L, Bachir D, Galacteros F, ''et al.'' |title=Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease |journal=Br. J. Haematol. |volume=108 |issue=2 |pages=284–9 |year=2000 |pmid=10691856 |doi=10.1046/j.1365-2141.2000.01861.x}}
+* {{cite journal  |vauthors=De Franceschi L, Bachir D, Galacteros F, etal |title=Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease |journal=Br. J. Haematol. |volume=108 |issue=2 |pages=284–9 |year=2000 |pmid=10691856 |doi=10.1046/j.1365-2141.2000.01861.x}}
 {{Mineral supplements}}